潜在陷阱:前列腺癌分期时[68Ga]-PSMA-11 PET/CT显示滤泡性淋巴瘤阳性
本文报道一例66岁前列腺癌患者,在行[68Ga]-PSMA-11 PET/CT分期时发现活检证实的滤泡性淋巴瘤呈PSMA阳性。该病例提示淋巴瘤可在PSMA PET/CT上模仿前列腺癌淋巴结转移,评估淋巴结分布与摄取时需仔细鉴别。
要点
- PSMA靶向PET是高风险前列腺癌分期的支柱手段。
- PSMA表达并非前列腺癌独有,也见于多种肿瘤和炎症状态。
- 淋巴瘤可在PSMA PET/CT上模仿前列腺癌淋巴结转移,需仔细评估淋巴结分布与摄取。
核心结论
- 本病例提示淋巴瘤在前列腺癌分期的PSMA PET/CT上模仿淋巴结转移是潜在陷阱。
研究设计与样本
- 本文为病例报告,报道一例66岁前列腺癌患者行[68Ga]-PSMA-11 PET/CT分期。
主要发现
- 该例活检证实的滤泡性淋巴瘤在[68Ga]-PSMA-11 PET/CT上呈阳性。
临床怎么用
- 作者强调评估PSMA PET/CT时需仔细评价淋巴结的分布与摄取,以区分淋巴瘤与前列腺癌转移。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA)-targeted PET agents are a mainstay in staging high-risk prostate cancer. Nevertheless, PSMA expression is not exclusive to prostate cancer and is present in various neoplasms and inflammatory conditions. We report a case of biopsy-proven follicular lymphoma positive on PSMA PET/CT originally performed for staging of prostate cancer in a 66-year-old patient. This case highlights the potential pitfall of lymphoma mimicking prostate cancer nodal metastasis on PSMA PET/CT and the importance of careful evaluation of distribution and uptake of lymph nodes when assessing PSMA PET/CT studies to distinguish lymphoma from prostate cancer metastases.
引用
- Heniche Y, Abikhzer G, McPherson V, et al. Potential Pitfall: Positive Follicular Lymphoma on [ 68 Ga]-PSMA-11 PET/CT for Prostate Cancer Staging. Clin Nucl Med. 2025. PMID: 40694857. doi:10.1097/RLU.0000000000006062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。